10.38
+0.28(+2.77%)
Currency In USD
| Previous Close | 10.1 |
| Open | 10.11 |
| Day High | 10.4 |
| Day Low | 9.83 |
| 52-Week High | 19.71 |
| 52-Week Low | 2.21 |
| Volume | 847,611 |
| Average Volume | 2.29M |
| Market Cap | 736.4M |
| PE | -2.22 |
| EPS | -4.67 |
| Moving Average 50 Days | 9.28 |
| Moving Average 200 Days | 7.41 |
| Change | 0.28 |
If you invested $1000 in Phathom Pharmaceuticals, Inc. (PHAT) since IPO date, it would be worth $421.95 as of August 20, 2025 at a share price of $10.38. Whereas If you bought $1000 worth of Phathom Pharmaceuticals, Inc. (PHAT) shares 5 years ago, it would be worth $258.27 as of August 20, 2025 at a share price of $10.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
GlobeNewswire Inc.
Jul 28, 2025 12:00 PM GMT
Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
GlobeNewswire Inc.
Jun 23, 2025 11:59 AM GMT
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appoi
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the